(325 days)
Not Found
No
The document describes a hematology control material used to monitor instrument reliability, not a device that processes data or makes decisions using AI/ML. There are no mentions of AI, ML, or related concepts.
No
The device is an in vitro diagnostic control material used to monitor the reliability of hematology instruments, not to treat or diagnose patients.
B. No.
This device is a control material used to monitor the reliability of hematology instruments, not to diagnose a patient's medical condition. It's an in vitro diagnostic use product.
No
The device description clearly states it is an "assayed, in vitro, whole blood control composed of human and bovine cells in a plasma-like fluid with preservatives," indicating it is a physical substance, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the control is "intended to monitor the reliability of hematology instruments that quantitatively measure red and white blood cell counts in cerebrospinal fluids, serous fluids, and synovial fluids." This describes a use in the diagnosis or monitoring of a disease or condition.
- "For in vitro Diagnostic Use Only": This phrase is clearly stated in the "Intended Use / Indications for Use" section. This is a strong indicator that the device is intended for in vitro diagnostic purposes.
- Device Description: The description mentions it is an "assayed, in vitro, whole blood control." The term "in vitro" means "in glass" or "in the lab," referring to tests performed outside of a living organism.
- Purpose: The control is used to monitor the performance of hematology instruments, which are used to analyze patient samples for diagnostic purposes.
Therefore, based on the provided information, the R&D Body Fluid-I Control is an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The R&D Body Fluid-I Control is an assayed hematology control intended to monitor the reliability of hematology instruments that quantitatively measure red and white blood cell counts in cerebrospinal fluids, serous fluids, and synovial fluids.
For in vitro Diagnostic Use Only
Product codes (comma separated list FDA assigned to the subject device)
JPK
Device Description
The R&D Body Fluid-I is an assayed, in vitro, whole blood control composed of human and bovine cells in a plasma-like fluid with preservatives. Three levels are available and each level of control is packaged in a tube containing 3 mL of the control material. It is sampled in the same manner as a patient specimen.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Three lots were tested to verify the closed vial and open vial stability and lot to lot reproducibility. Each lot of control material (each lot containing 3 levels) were stored at 2 - 8° C and tested at real time points at approximately every other week on three different instruments for the purpose of evaluating closed vial stability.
Open vial stability was assessed on three lots of control material (each lot containing 3 levels) and tested near the end of their closed vial shelf life to reflect a worse case scenario. The controls were stored at 2 - 8° C until they were tested. The testing was done according to the instructions for use through at least 30 days and run on one analyzer.
The Body Fluid-I Hematology Control passed the acceptance criteria of remaining within range over the life of the product.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.8625 Hematology quality control mixture.
(a)
Identification. A hematology quality control mixture is a device used to ascertain the accuracy and precision of manual, semiautomated, and automated determinations of cell parameters such as white cell count (WBC), red cell count (RBC), platelet count (PLT), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC).(b)
Classification. Class II (special controls). Except when intended for use in blood components, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: _______________________________________________________________________________________________________________________________________________
Submitter Information
| Manufacturer: | |
|---|---|
| Address: |
| Contact: | |
|---|---|
| Phone: | |
| Fax: | |
| Date Prepared: |
R&D Systems, Inc. 614 McKinley Place N.E. Minneapolis, MN 55413 Nancy Ring 612-656-4533 612-379-6580 4/21/2011
Device Information
Trade Name: Common Name: Classification Name: Classification: Product Code: Device Class: Panel:
Body Fluid-I Hematology Control Hematology Control Hematology quality control mixture 21 CFR 864.8625 JPK II Hematology (81)
Predicate Device
Trade Name: 510(k) number: Date:
Streck Cell-Chex™ Auto Hematology Control K053362 January 13th, 2006
Description of Device
The R&D Body Fluid-I is an assayed, in vitro, whole blood control composed of human and bovine cells in a plasma-like fluid with preservatives. Three levels are available and each level of control is packaged in a tube containing 3 mL of the control material. It is sampled in the same manner as a patient specimen.
Intended Use:
Body Fluid-I Control is an assayed hematology control intended to monitor the reliability of hematology instruments that quantitatively measure red and white blood cell counts in cerebrospinal fluids, serous fluids, and synovial fluids.
1
R & D Systems, Inc. Body Fluid-I Hematology Control
Comparison to Predicate
Like the previously cleared predicate device, the Body Fluid-I Hematology Control is an assayed whole blood control for evaluating the accuracy and precision of hematology instruments that measure blood cell counts in patient body fluid samples.
The difference is the predicate device's biological source is human whereas the Body Fluid-I contains human and bovine biological sources.
Summary of Data
Three lots were tested to verify the closed vial and open vial stability and lot to lot reproducibility. Each lot of control material (each lot containing 3 levels) were stored at 2 - 8° C and tested at real time points at approximately every other week on three different instruments for the purpose of evaluating closed vial stability.
Open vial stability was assessed on three lots of control material (each lot containing 3 levels) and tested near the end of their closed vial shelf life to reflect a worse case scenario. The controls were stored at 2 - 8° C until they were tested. The testing was done according to the instructions for use through at least 30 days and run on one analyzer.
The Body Fluid-I Hematology Control passed the acceptance criteria of remaining within range over the life of the product.
Conclusions Drawn From Tests:
The R&D Systems Body Fluid-I Hematology Control is as safe and effective as the predicate device and is an effective quality control material for evaluating the accuracy and precision of hematology instruments that measure blood cell counts in patient body fluid samples when used as indicated on the labeling. It meets the claim of a 75 day closed vial, and 30 day open vial stability and results confirm lot-to-lot consistency.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure with three curved lines representing its body and wings.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
APR 2 8 2011
R&D Systems, Inc. c/o Ms. Nancy Ring Sr. Quality Assurance/Regulatory Affairs Specialist 614 McKinley Place N.E. Minneapolis, MN, 55413
Re: K101578 Trade/Device Name: Body Fluid-I Hematology Control Regulation Number: 21 CFR 864.8625 Regulation Name: Mixture, Hematology Quality Control Regulatory Class: Class II Product Code: JPK Dated: April 8, 2011 Received: April 12, 2011
Dear Ms. Ring:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter
3
Page 2 - Ms. Nancy Ring
will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
ia m chen
Maria M. Chan, Ph.D Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):
Device Name: R&D Body Fluid-I Hematology Control
Indications for Use:
The R&D Body Fluid-I Control is an assayed hematology control intended to monitor the reliability of hematology instruments that quantitatively measure red and white blood cell counts in cerebrospinal fluids, serous fluids, and synovial fluids.
For in vitro Diagnostic Use Only
Prescription Use _ X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use _ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Page 1 of ____________________________________________________________________________________________________________________________________________________________________ Division Sign-Office of In Vitro Diagnostic Device Evaluation and Safety